American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Tallman
    Tallman
  5. Perales
    Perales
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Kernan
    Kernan
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (3847)
  2. Hematologic Malignancies, Division of (3642)
  3. Center for Hematologic Malignancies (3544)
  4. GSK Faculty (1553)
  5. Adult Leukemia (1290)
  6. Sloan Kettering Institute Faculty (1065)
  7. Bone Marrow Transplant (936)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (931)
  9. Lymphoma (899)
  10. Tow Center for Developmental Oncology (TCDO) (863)
Search Within
Formats
  1. Meeting Abstract (4152)
  2. Journal Article (1242)
  3. Research Letter (44)
  4. Review (44)
  5. Editorial (34)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (3847)
  2. Hematologic Malignancies, Division of (3642)
  3. Center for Hematologic Malignancies (3544)
  4. GSK Faculty (1553)
  5. Adult Leukemia (1290)
  6. Sloan Kettering Institute Faculty (1065)

More Groups

People
  1. Sergio Giralt (337)
  2. Andrew Zelenetz (328)
  3. Ross Levine (312)
  4. Martin Tallman (298)
  5. Miguel-Angel Perales (292)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (46)
  2. 2024 (430)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5167)
  2. Blood Advances (322)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5539)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A hyperactive signalosome results in high sensitivity to HSP90 inhibitors in AML
    Meeting Abstract

    Zong, H. L.; Taldone, T.; Roboz, G. J.; Chiosis, G.; Guzman, M. L.
    Blood (2015)

    Fulltext@MSK | Save
  • Astarabine, a pro-drug of cytarabine, is safe for patients with advanced acute leukemia. A phase I/IIa single center study in relapsed/refractory or medically unfit patients
    Meeting Abstract

    Zuckerman, T.; Ben Yakar, R.; Gengrinovitch, S.; Hoffman, R.; Henig, I.; Lavi, N.; Akria, L.; Ofran, Y.; Nudelman, O.; Haddad, N.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Global 3' UTR sequencing in multiple myeloma (MM)
    Meeting Abstract

    Singh, I.; Samur, M. K.; Lee, S. H.; Sperling, A. S.; Tai, Y. T.; Fulciniti, M.; Leslie, C. S.; Mayr, C.; Munshi, N. C.
    Blood (2015)

    Fulltext@MSK | Save
  • Reduced emergency room utilization for initiation of anticoagulation with rivaroxaban versus Low Molecular Weight Heparin for treatment of cancer-associated thrombosis
    Meeting Abstract

    Soff, A. P.; Dong, J.; Dong, A.; Devlin, S.; Mantha, S.; Parameswaran, R.; Soff, G. A.
    Blood (2015)

    Fulltext@MSK | Save
  • Veliparib (ABT-888), bendamustine, and rituximab (VBR) is well tolerated and efficacious in patients with lymphoma: Final analysis of a phase 1b clinical trial of VB and a cohort expansion of VBR in patients with B-cell lymphoma
    Meeting Abstract

    Soumerai, J. D.; Zelenetz, A. D.; Moskowitz, C. H.; Younes, A.; Palomba, M. L.; Hamlin, P. A. Jr; Noy, A.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • A phase 1 study of the DOT1L inhibitor, pinometostat (EPZ-5676), in adults with relapsed or refractory leukemia: Safety, clinical activity, exposure and target inhibition
    Meeting Abstract

    Stein, E. M.; Garcia-Manero, G.; Rizzieri, D. A.; Tibes, R.; Berdeja, J. G.; Jongen-Lavrencic, M.; Altman, J. K.; Dohner, H.; Thomson, B.; Blakemore, S. J.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • PRMT1-mediated methylation of DUSP4 determines megakaryocyte-erythroid lineage choice by regulating p38 signaling
    Meeting Abstract

    Su, H. R.; Tran, N. T.; Guo, H.; Luo, M.; Zhao, X. T.
    Blood (2015)

    Fulltext@MSK | Save
  • Updated efficacy and safety data from the AETHERA trial of consolidation with brentuximab vedotin after autologous stem cell transplant (ASCT) in Hodgkin lymphoma patients at high risk of relapse
    Meeting Abstract

    Sweetenham, J.; Walewski, J.; Nademanee, A. P.; Masszi, T.; Agura, E.; Holowiecki, J.; Abidi, M. H.; Chen, A. I.; Stiff, P.; Viviani, S.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Impact of busulphan exposure on transplant outcomes for patients with advanced myelodysplastic syndromes undergoing CD34 selected allogeneic hematopoietic cell transplantation
    Meeting Abstract

    Tamari, R.; Proli, A.; Zheng, J. T.; Jakubowski, A. A.; Papadopoulos, E. B.; Ponce, D. M.; Devlin, S.; Sauter, C. S.; Young, J. W.; Giralt, S. A.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Targeting CD99 in T-cell neoplasms with monoclonal antibodies
    Meeting Abstract

    Tavakkoli, M.; Lee, D. H.; Durham, B.; Chung, S. S.; Park, C. Y.
    Blood (2015)

    Fulltext@MSK | Save